Sorry, you need to enable JavaScript to visit this website.

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Sign-up to receive all GMG announcements, including Request for Proposal (RFP) postings.

Sign Up for Alerts
Title
Grant Type
Focus Area
Country
Application Due Date
Research in Ulcerative Colitis (UC) 2024
Release Date:
Review Process: Expert Review Panel
Research Inflammation & Immunology Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Spain, Switzerland, United Kingdom
Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma
Release Date:
Review Process: Pfizer Internal
Research Oncology USA
BCMA-Directed Bispecific Antibody Treatment in Multiple Myeloma
Release Date:
Review Process: Pfizer Internal
Translation: Japanese (link)
Education Oncology Japan
Research on MBL producing Enterobacterales and/or Stenotrophomonas maltophilia
Release Date:
Review Process: Pfizer Internal
Research Hospital Austria, Brazil, China, France, Germany, Greece, India, Italy, Mexico, Saudi Arabia, Spain, Taiwan, Turkey, United Kingdom
Increase Awareness & Understanding of Emerging Hemophilia Treatment Options (Global excluding United States)
Release Date:
Review Process: Pfizer Internal
Education Rare Disease All
Optimal management of patients with prostate cancer receiving androgen deprivation therapy (ADT)
Release Date:
Partner: Sumitomo Pharma
Review Process: Pfizer Internal
Education Oncology USA
Title
Grant Type
Focus Area
Country
Application Due Date
Transition of Care in VTE
Release Date:
Anticoagulation Education - NVAF or VTE
Release Date:
Review Process:
Achievement of Treat-to-Target in Rheumatoid Arthritis
Release Date:
Improving Care of Chronic Pain- Physician Groups and Health Systems
Release Date:
Facilitation of the Diagnosis of Rheumatoid Arthritis
Release Date:
Pfizer and NCCN: Metastatic Breast Cancer
Release Date:
Pediatric Immunization Series Completion
Release Date:
Pfizer and National Psoriasis Foundation (NPF): Plugging the Treatment Gap in Psoriasis and Psoriatic Arthritis
Release Date:
Pfizer and International Atherosclerosis Society (IAS): Lipid Management in High-Risk Patients
Release Date:
Pfizer and American Academy of Dermatology (AAD): Patient Access to Care
Release Date:
Narrowing the Time Gap between Onset of Symptoms and Treatment for Rheumatoid Arthritis
Release Date: